WO2019223688A1 - Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne - Google Patents

Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne Download PDF

Info

Publication number
WO2019223688A1
WO2019223688A1 PCT/CN2019/087821 CN2019087821W WO2019223688A1 WO 2019223688 A1 WO2019223688 A1 WO 2019223688A1 CN 2019087821 W CN2019087821 W CN 2019087821W WO 2019223688 A1 WO2019223688 A1 WO 2019223688A1
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid hormone
thrβ
hypothyroidism
hormone receptor
compound
Prior art date
Application number
PCT/CN2019/087821
Other languages
English (en)
Chinese (zh)
Inventor
李勇
姚本强
Original Assignee
厦门大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门大学 filed Critical 厦门大学
Publication of WO2019223688A1 publication Critical patent/WO2019223688A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Definitions

  • the invention relates to the use of FG-4592 as a thyroid hormone receptor THR agonist, in particular to the application of the compound FG-4592 in the preparation of a pharmaceutical preparation for treating a thyroid hormone receptor-mediated disease.
  • FG-4592 is a HIF ⁇ prolyl hydroxylase inhibitor that also induces EPO production and is used clinically to treat anemia associated with chronic kidney disease and end-stage renal disease.
  • the oral small molecule stabilizes the heterodimer of HIF1 ⁇ and HIF ⁇ by inhibiting the hypoxia-inducible factor HIF1 ⁇ hydroxylase, thereby regulating downstream target genes, promoting the production of erythropoietin (EPO), inhibiting inflammation, and down-regulating hepcidin levels (Free iron storage hormone) and up-regulate other iron-promoting genes to ensure effective mobilization and utilization of the body's own stored iron. Red blood cell production in the process of restoring the body's natural balance (Beuck, S., W. Schanzer, and M. Thevis, Drug Test Anal, 2012.4 (11): p.830-45).
  • Thyroid hormone receptors are very important members of the 48 nuclear receptors in the human body. There are two types of THR ⁇ and THR ⁇ . THRs promote the growth, differentiation and metabolism of the human body under the regulation of transcriptional activation of the natural ligand agonists thyroid hormones T3 and T4.
  • the principle of THR-mediated pharmacological action is: Thyroid hormone ligands bind to the ligand binding domain (LBD) of THR and affect the recruitment of various co-activators (or co-inhibitors) by inducing THR receptor conformational changes ), Such as the co-activator SRC1, which in turn regulates the transcription of downstream target genes.
  • Thyroid production of T4 and T3 is under multiple negative feedback regulation.
  • TSH also called thyroid stimulating hormone
  • TSH is responsible for normal thyroid function and regulation of thyroid hormone secretion.
  • TSH is synthesized in the pituitary gland chiba, and its secretion is controlled by the thyroid stimulating hormone releasing hormone (TRH) synthesized in the hypothalamus.
  • TRH thyroid stimulating hormone releasing hormone
  • this neuro- and hormonal feedback regulation maintains body weight, metabolic rate, body temperature, mood, and affects serum low-density lipoprotein (LDL) levels. Therefore, there is weight gain, diabetes, hypertriglyceridemia, hypercholesterolemia, atherosclerosis, obesity, and endocrine system diseases when thyroid function is degraded or under thyroid hormone resistance.
  • hypothyroidism refers to a clinical syndrome caused by thyroid hormone deficiency due to different reasons, which causes the body's metabolism and the function of each system in the body to decline. According to its cause, it is divided into primary hypothyroidism, secondary hypothyroidism and peripheral hypothyroidism.
  • Clinical manifestations include memory loss, mental retardation, drowsiness, ataxia; bradycardia, reduced cardiac output, and concurrent coronary heart disease; anorexia, bloating, constipation, which can lead to malignant anemia and iron deficiency anemia; muscle weakness, pain , Rigidity, may be accompanied by joint lesions such as chronic arthritis; women with more menstrual periods, chronic disease, amenorrhea, infertility; male impotence, hyposexuality; when the condition is severe, improper stress can induce coma, shock, and heart and kidney failure Waiting; minor illness; juvenile hypothyroidism such as short stature, low intelligence, delayed sexual development; and non-shiatsu edema (Myxedema).
  • TTR thyroid hormone receptor
  • Thyroid hormone resistance syndrome thyroid Hormone resistance syndrome
  • THIS thyroid hormone insensitivity syndrome
  • Systemic thyroid hormone refractory disease which involves the pituitary gland and surrounding tissues. This type can be divided into normal thyroid function compensatory normal type and hypothyroidism type;
  • Selective pituitary is refractory to thyroid hormones, which is characterized by a lot of pituitary involvement and does not respond to thyroid hormones, while the remaining peripheral tissues are not affected and can respond to thyroid hormones normally. Its clinical manifestations are hyperthyroidism; 3.
  • Peripheral tissues should be refractory to thyroid hormones. This type is characterized by the surrounding tissues not responding or insensitive to thyroid hormones, while the pituitary gland is mostly unaffected and responds normally to thyroid hormones. Clinical manifestations of goiter, no deafness and epiphyseal changes. Although the thyroid hormone is normal and TSH is normal, the clinical manifestations of hypothyroidism, bradycardia, edema, fatigue, abdominal distension and constipation are abnormal. This type can be manifested as poor intelligence, lagging development, or having mature bones.
  • thyroid hormone resistance syndromes are caused by mutations in the thyroid hormone receptor THRs gene, which causes changes in the amino acid sequence of the thyroid hormone receptor, leading to changes in the structure and function of the receptor, and resistance or insensitivity to the thyroid hormones T3 and T4. . Therefore, looking for thyroid hormone receptor agonists that are structurally different from the natural thyroid hormones T3 and T4 is expected to treat thyroid hormone resistance syndrome.
  • Hyperthyroidism referred to as “hyperthyroidism,” is a condition in which the thyroid gland releases excessive thyroid hormones, causing the body's metabolic metabolism and sympathetic nerve excitement to cause palpitations, sweating, eating, increased stool frequency, and weight loss. Most patients also have symptoms such as exophthalmos, eyelid edema, and vision loss.
  • Affective mental disorder caused by thyroid hormone homeostasis is one of the causes of individual illness. Although patients may show short-term thyroid function, in the subgroup of patients, the incidence of clinical hypothyroidism and hyperthyroidism is manifested. For a significant increase. Thyroid hormones are essential for the development of the central nervous system, especially the brain. Patients with mental illness, especially cognitive impairment and depression, are closely related to thyroid hormone metabolism and abnormal thyroid system immune function. Therefore, thyroid hormone is frequently used to accelerate and enhance the treatment of antidepressant drugs, support the maintenance treatment of bipolar disorder and affective disorders, even in patients with normal thyroid function (Bauer, M., et al., Mol Psychiatry, 2002.7 (2 ): p.140-56).
  • thyroid hormone T4 in patients with hypothyroidism leads to improvement in mood and learning ability, and positive experimental results are positively correlated with increased free thyroid hormone concentrations (Bunevicius, R., CurrOpin Psychiatry, 2009.22 (4): p.391-5 ).
  • Thyroid hormones have an important effect on the central nervous system, and mental disorders, especially emotional disorders, are often associated with thyroid hormone metabolism disorders in the brain (Bauer, M., et al., J Neuroendocrinol, 2008.20 (10): p.1101 -14).
  • T3 has been used to treat patients with depression alone or in combination with other antidepressants to enhance or accelerate the effect of antidepressants on patients with thyroid depression.
  • T3 and tricyclic antidepressants have significantly accelerated tricyclic antidepressants in clinical trials for the treatment of antidepressants, showing the obvious efficacy of this treatment method (Aronson, R., et al., Arch Gen Psychiatry, 1996.53 (9): p.842-8).
  • the effectiveness and safety of T3 in combination with another mainstream antidepressant, selective serotonin transporter inhibitors, for the treatment of major depression have also been demonstrated (Cooper-Kazaz, R. and B. Lerer, Int J Neuropsychopharmacol, 2008.11 (5): p.685-99).
  • Thyroid hormone regulates lipid and cholesterol metabolism through THR ⁇ .
  • the clinical use of natural thyroid hormone and thyroid receptor agonists to treat hypercholesterolemia is only used in patients with thyroid dysfunction. The reason is that non-specific agonists activate the THR ⁇ receptor, which has a negative impact on cardiovascular disease. Therefore, finding efficient and specific activation of THR ⁇ instead of THR ⁇ will become a solid direction for the treatment of a series of diseases caused by abnormal lipid metabolism and high cholesterol. Therefore, it is still necessary to find effective and specific thyroid hormone receptor ⁇ agonists, regulate lipid metabolism, and lower cholesterol to treat diseases such as dyslipidemia, fatty liver, hypercholesterolemia, and atherosclerosis.
  • thyroid hormone receptor beta-specific agonists can protect liver tissue, promote liver function, and treat non-alcoholic fatty liver (NAFLD).
  • NAFLD non-alcoholic fatty liver
  • the research progress in the data published by Madrigal Pharmaceuticals is praised as a new and effective way to treat non-alcoholic steatohepatitis beyond FXR, PPAR ⁇ / ⁇ .
  • Another scientist, Kim D, and others found that non-alcoholic steatohepatitis (NASH) and liver fibrosis in patients with subclinical hypothyroidism are directly related to their hypothyroidism.
  • NASH non-alcoholic steatohepatitis
  • Non-alcoholic steatohepatitis and advanced fibrosis were higher in subjects with lower thyroid function.
  • T3 has not shown any selectivity in combining two THR subtypes (THR ⁇ and THR ⁇ ). Therefore, although administration of T3 can reduce plasma cholesterol, low-density lipoprotein (LDL), and triglyceride levels in animal models and humans, however, due to side effects of T3 on the heart (such as tachycardia, arrhythmia, and muscleshrinking), limiting its application.
  • LDL low-density lipoprotein
  • thyroid hormone agonists are mainly to increase the selective activation of THR ⁇ and reduce the activation of THR ⁇ .
  • Another major problem is the adverse effects of genetic mutations.
  • Thyroid hormone resistance (Refetoff syndrome) describes a rare symptom of elevated thyroid hormone levels, but thyroid stimulating hormone (TSH) levels are not suppressed or are not expected to be completely suppressed. In essence, this reduces the response of thyroid hormone effectors to thyroid hormones (Refetoff, S., et al., J Clin Endocrinol Metab, 1967.27 (2): p.279-94).
  • thyroid hormone receptor protein Mutations of thyroid hormone receptor protein have rendered the original natural ligands such as T3 and a variety of THR ⁇ selective agonists ineffective. New drugs suitable for polythyroxine resistance syndrome Urgent development.
  • the purpose of the present invention is to use the compound FG-4592 (or hydroxyquinine drugs) in the preparation of an thyroid hormone receptor (THR) agonist, and in the preparation of thyroid hormone receptor-mediated Application in pharmaceutical preparations.
  • TTR thyroid hormone receptor
  • the compound FG-4592 or a pharmaceutically acceptable salt thereof can be used in preparing an agonist of thyroid hormone receptor (THR), the THR includes THR ⁇ and THR ⁇ , and the agonist includes a full agonist Or partial agonist.
  • THR thyroid hormone receptor
  • the agonist includes a full agonist Or partial agonist.
  • the compound FG-4592 or a pharmaceutically acceptable salt thereof can be used in preparing a selective agonist of THR ⁇ .
  • the compound FG-4592 or a pharmaceutically acceptable salt thereof can be used in preparing a pharmaceutical preparation for preventing or treating a thyroid hormone receptor-mediated disease.
  • the thyroid hormone receptor-mediated diseases include hypothyroidism, hypothyroidism, polythyroid hormone resistance syndrome, mental illness, non-alcoholic fatty liver, and the like.
  • the mental illness includes, but is not limited to, attention deficit hyperactivity disorder (ADHD), depression, mental retardation, and cognitive dysfunction.
  • ADHD attention deficit hyperactivity disorder
  • the polymorphic thyroid hormone resistance syndrome includes, but is not limited to, diseases caused by mutations in the THR ⁇ receptor protein ligand binding domain known clinically.
  • the THR ⁇ site mutations include, but are not limited to, V264D, A268D , R282S, V283A, M310T, E311K, S314C, A317T, R320C, N331D, G332E, G332R, L346F, L346V, H435L, R438H, F459C, F459L, etc.
  • the compound FG-4592 or a pharmaceutically acceptable salt thereof can be used in the preparation of a pharmaceutical composition used in combination with other pharmaceutical preparations for preventing or treating thyroid hormone receptor-mediated diseases.
  • the compound FG-4592 is a pharmaceutical composition that includes an effective dose of FG-4592 or a pharmaceutically acceptable salt thereof.
  • the compound FG-4592 has a good THR agonistic effect.
  • compound FG-4592 can bind to nuclear receptor thyroid hormone receptor (THR), induce THR to recruit co-regulatory factors, and activate the expression of target genes of THR.
  • THR nuclear receptor thyroid hormone receptor
  • the compound is a small molecule "regulator” or "THR ligand” of the nuclear receptor THR, and therefore, it can be used as a THR agonist for preventing or treating related diseases mediated by THR.
  • the THR agonist includes a full agonist or a partial agonist of THR ⁇ and THR ⁇ .
  • AlphaScreen experiments show that FG-4592 can induce THR ⁇ and THR ⁇ to recruit co-activators. Because coactivators can directly activate the THR downstream pathway, FG-4592 is an agonist of the nuclear receptor THR.
  • Reporter gene experiments show that FG-4592 can activate the transcriptional activity of nuclear receptors THR ⁇ and THR ⁇ on its target genes, indicating that FG-4592 is an agonist of nuclear receptor THR.
  • the X-ray crystal diffraction method further elucidates the binding mode of THR ⁇ and FG-4592 from the atomic level. Therefore, multiple methods have been used to prove that FG-4592 thyroid hormone receptor THR agonists can be used as thyroid hormone analogs to prevent or treat related diseases mediated by THR.
  • FG-4592 significantly activates the transcriptional activity of THR ⁇ mutants with polymorphic thyroid hormone resistance syndrome and can be used to treat thyroid hormone resistance syndrome.
  • X-ray crystal diffractometry showed that these mutants changed the conformation of THR ligand binding domain (LBD) and lost their strong binding ability to thyroid hormones T3 and T4.
  • LBD THR ligand binding domain
  • FG-4592 has significantly different structures from thyroid hormones T3 and T4. Therefore, FG-4592 can bind to these THR ⁇ receptor protein site lesions and significantly activate their transcriptional activity. Therefore, FG-4592 can be used to treat thyroid hormone resistance synthesis Sign.
  • FG-4592 is an agonist of nuclear receptor THR ⁇ . It can regulate the functions of THR ⁇ involved in endocrine metabolism such as energy metabolism, lipid metabolism, cholesterol-cholic acid metabolism, and nervous system functions in combination with the target THR ⁇ . Adjustment.
  • FG-4592 is a hydroxyquinine drug that can be used to treat chronic kidney disease anemia (CKD) by oral administration. It is mainly used in the second generation of hypoxia-inducible factor proline hydroxylase inhibitor (HIF-PHI). Nephropathy and anemia associated with end-stage renal disease. So far, there have been no reports about its combination with THRs and its use in drugs that treat thyroid hormone receptor-mediated diseases such as thyroid hormone resistance, hypothyroidism, or hypothyroidism. Therefore, the FG-4592 given in the present invention has therapeutic functions in these diseases, and it is all about the new application method of FG-4592, which is creative.
  • CKD chronic kidney disease anemia
  • HIF-PHI hypoxia-inducible factor proline hydroxylase inhibitor
  • Thyroid hormone receptor-mediated diseases such as thyroid hormone resistance, hypothyroidism, or hypothyroidism seriously affect human health and life. Therefore, the FG-4592 given in the present invention is useful in the preparation of pharmaceutical preparations for the treatment of these major diseases. Practical functions, which have important social value and huge economic value, are practical.
  • the compounds in the methods described herein can be formulated into pharmaceutical compositions for use in some dosing regimens.
  • the composition of the medicament of the present invention may contain the compound itself and a salt or a carrier for administration thereof. Such compositions may also optionally contain other therapeutic agents.
  • agents or therapies may be administered in combination with the compounds described herein, such as antidepressants, various THR ligands, cytokine antagonists, immunosuppressants, cytokines, growth factors, immunomodulators, prostaglandins or Anti-hyperplasia compounds.
  • the term "combination" and its related terms used in the present invention sequentially correspond to that the therapeutic agent and the compound of the present invention are administered simultaneously or sequentially.
  • a certain compound may be administered simultaneously or sequentially with another therapeutic agent in a single unit dosage form.
  • the present invention provides a single unit dosage form comprising the compound, an additional therapeutic agent.
  • therapeutic effects are generally considered to work in a "combination”.
  • Acid salts include: acetate, adipate, alginate, aspartate, benzoate, besylate, bisulfate, butyrate, citrate, camphor, camphor Sulfonate, cyclopentane, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptanoate, glyceryl phosphate, hemisulfate, heptanoate, hexanoate , Hydrochloride, hydrobromide, hydroiodate, 2-hydroxyethanesulfonate, lactate, maleate, mesylate, 2-naphthalenesulfonate, nicotinate, oxalic acid Salt, paraben, pectate, persulfate, 3-phenylpropionate, pic
  • Alkali salts include ammonium, alkali metal, alkaline earth metal and organic base salts; the alkali metal salts include sodium and potassium salts, the alkaline earth metal salts include calcium and magnesium salts, and the organic base salts include bicyclic One of hexylamine salt, N-methyl-D-glucosamine salt, or salt with amino acid such as arginine, lysine and the like.
  • the pharmaceutical composition of the present invention can be formulated into solid or liquid forms, including the following suitable forms of administration: (1) oral administration, such as potions (aqueous or non-aqueous solutions or suspensions), tablets, cheeks, tongue Subcutaneous and systemic absorbents, boluses, powders, granules, sublingual pastes; (2) parenteral administration, prepared as sterile solutions or suspensions or sustained release agents, by subcutaneous, intramuscular, intravenous Or epidural injection; (3) topical applications such as creams, ointments, controlled release patches or sprays for the skin, lungs, or mouth; (4) intrarectal administration, such as as an emulsion or foam; ( 5) Others: sublingual, ophthalmic, percutaneous or nasal, pulmonary and other mucosal intake.
  • oral administration such as potions (aqueous or non-aqueous solutions or suspensions), tablets, cheeks, tongue Subcutaneous and systemic absorbents, boluses, powders, granules, sublingual pastes
  • the method for preparing the pharmaceutical composition of the compound includes combining the compound FG-4592 with a carrier or a plurality of auxiliary ingredients in any process.
  • compound FG-4592 can be prepared by uniformly and intimately combining with a carrier (liquid carrier, finely divided solid carrier, or both), and the product can be shaped as required.
  • the effect can be prolonged by slowing the slow absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by preparing liquid suspensions of crystalline or amorphous substances with poor water solubility.
  • the absorption rate of a drug depends on its dissolution rate, which in turn may depend on the crystal size and crystalline form.
  • parenteral administration can be delayed by dissolving or suspending the drug in an oily carrier.
  • the injectable drug depot form can be made by combining the compound with a biodegradable polymer (such as polylactide-polyglycolide) in a microcapsule matrix. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled.
  • a biodegradable polymer such as polylactide-polyglycolide
  • Other biodegradable polymers include polyorthoesters and polyanhydrides. It is also possible to prepare injectable drug depot formulations compatible with body tissues by embedding the drug in liposomes or microemulsions.
  • the pharmaceutical ingredients of the present invention can be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • the usual coatings are lactose and corn starch, and lubricants such as magnesium stearate are usually added.
  • useful diluents include lactose and dried corn starch.
  • the pharmaceutically active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and / or flavoring and / or coloring agents may be added.
  • the pharmaceutical ingredients of the present invention can be administered as an aerosol or inhalant.
  • Such agents can be prepared according to techniques widely used in the field of pharmaceutical formulation, or they can be prepared as saline solutions.
  • Such prior art often uses benzyl alcohol or other suitable preservatives, fluorocarbons and / or other solubilizing or dispersing agents, absorption enhancers to increase their bioavailability.
  • transdermal patches are to achieve controlled delivery of the compounds of the invention to the body.
  • This dosage form can be prepared by dissolving or dispersing the compound in an appropriate medium.
  • Absorption enhancers can be used to increase the skin's absorption of the compound, or by using a rate-controlling film or dispersing the compound in a polymer matrix or gel, the rate of compound passing through the skin can be controlled.
  • FG-4592 is a specific ligand for THR obtained through high-throughput screening.
  • the effects of compounds inducing THR and co-activators or co-inhibitors were detected by AlphaScreen biochemical methods. Based on the analysis of luciferase reporter gene activity and molecular structure level in cell transfection experiments, the specific and selective recognition of this receptor and ligand was explained to further verify the compound's transcriptional activation effect on THR.
  • Thyroid hormone T3 lost significant activation of the transcription of all the reporter genes in the table, but FG-4592 Significant activation of the transcriptional activity of these THR ⁇ mutants.
  • the complex was prepared from THR ⁇ / FG-4592, and the complex was crystallized, X-ray crystal diffracted, and structurally analyzed by X-ray crystal diffractometry.
  • the bonding mode of THR ⁇ and FG-4592 was clarified from the atomic level. Therefore, the present invention has discovered and verified that FG-4592 is a new type of THR agonist by combining various methods such as biochemistry, molecular biology and structural biology. Interestingly, FG-4592 can activate THR-mediated transcriptional activity as well as thyroid hormone T3, and also significantly activate THR ⁇ mutant transcriptional activity that is resistant to thyroid hormone T3.
  • Figure 1 shows that FG-4592 promotes the interaction of the SRC coactivator LXXLL motif with THR ⁇ and THR ⁇ .
  • the abscissa represents several biotin-labeled coregulatory polypeptides that contain the LXXLL motif that binds to THR.
  • FIG. 2 is a dose-response curve for measuring the relative activity of FG-4592 to regulate THR ⁇ and THR ⁇ recruitment of co-activator SRC1LXXLL motifs by AlphaScreen assay.
  • FIG. 3 is a dose-response curve of cell-based luciferase assay for FG-4592 to regulate THR ⁇ and THR ⁇ transcriptional activity.
  • the mammalian two-hybrid method was used to clone THRLBD into a pBind expression vector, which can express a Gal4 tag fusion protein in the cell.
  • This plasmid and pG5-luc luciferase reporter gene plasmid were co-transfected into 293T cells. After transfection, cells were treated with compounds, and the effects of reporter gene transcription activity were examined after treatment with various compounds. All experiments were performed in triplicate independently.
  • FIG. 4 is a three-dimensional crystal structure diagram of a complex in which FG-4592 and THR ⁇ are combined.
  • the band diagram shows the structure of the nuclear receptor THR ⁇ protein, labeled with the name of the relevant alpha helix.
  • the bar graph shows the structure of the ligand FG-4592 compound.
  • Figure 5 is a two-dimensional schematic diagram of the amino acid interaction between FG-4592 and the thyroid hormone receptor THR ⁇ ligand binding domain.
  • the hydrophobic phenyl end of the ligand forms a hydrophobic interaction with nearby nonpolar amino acids, while the carboxyl end of the ligand mainly forms hydrogen bonds directly with polar amino acids or forms a hydrogen bond network with polar amino acids through water.
  • the gray arrows and black straight lines indicate that the ligand forms hydrogen bonds and hydrophobic interactions with amino acid residues, respectively.
  • Fig. 6 shows that the hydrophobic phenyl group of FG-4592 gives it the ability to selectively bind to THR ⁇ .
  • the structures of T3 / THR ⁇ LBD (gray) and FG-4592 / THR ⁇ LBD (black) are superimposed and compared.
  • the arrows indicate the backbone and single residues between THR ⁇ and THR ⁇ that help FG-4592 selectively bind to the receptor THR ⁇ . Differential conformation of the basal side chain.
  • FIG. 7 is a comparison diagram of the conformational superposition of FG-4592 and other THR ligands in the THR ⁇ pocket.
  • FG-4592 shares a conserved carboxyl head (upper black arrow) but does not share a hydroxy tail (lower black arrow) with other THR ligands.
  • the unique hydrophobic phenyl extension of FG-4592 is indicated by the gray arrow.
  • FIG 8 is the structural mechanism of FG-4592 activating THR ⁇ mutants associated with thyroid hormone resistance.
  • Conformational changes in residues involved in thyroid hormone resistance caused by THR ⁇ mutations are indicated by red arrows. Mutant residues are shown in salmon red.
  • the key hydrogen bonds formed between the THR ⁇ H435 residue and the thyroid hormone T3 are marked with arrows.
  • Example 1 demonstrates that FG-4592 enhances the ability of THR ⁇ and THR ⁇ to recruit co-activators and is an agonist of thyroid hormone receptor THR.
  • Figure 1 shows that FG-4592 promotes the interaction of the SRC coactivator LXXLL motif with THR ⁇ and THR ⁇ .
  • the effect of FG-4592 with a final concentration of 1 ⁇ M on the interaction of LBD of THR ⁇ and ⁇ R ⁇ with various co-regulators including the SRCLXXLL motif was detected using AlphaScreen technology.
  • the N-terminal biotinylated cofactor polypeptide sequence is:
  • SRC2-3 QEPVSPKKKENALLRYLLDKDDTKD.
  • SRC3-3 PDAASKHKQLSELLRGGSG;
  • THR ⁇ LBD amino acid residues 148-410
  • THR ⁇ LBD amino acid residues 202-461
  • the constructed vector was transformed into E. coli BL21 (DE3) and cultured at 30 ° C until the OD600 was about 0.8. The temperature was lowered to 22 ° C, and 0.1 mM isopropyl 1-thio- ⁇ -D-galactoside (IPTG) was added. ) Induce target protein expression for 6h.
  • IPTG isopropyl 1-thio- ⁇ -D-galactoside
  • coli cells were subsequently centrifuged (4200 r.p.m.) for 30 min, resuspended in buffer (25 mM Tris pH 7.5, 25 mM imidazole, 150 m sodium chloride) on ice and frozen at -70 ° C for 2 h.
  • the lysed cell solution was centrifuged (> 20,000 r.p.m.) at 4 ° C for 30 min, and the supernatant was taken and applied to a nickel ion exchange column (NiSO4-loaded HiTrap HP column, GE Healthcare) of GE.
  • the nickel column loaded with the sample was eluted in a gradient of 25 to 500 mM imidazole in an AKTA pure protein purification instrument from GE.
  • the eluted protein was further purified using an anion exchange column (Q-Sepharose column).
  • the LBD proteins of THR ⁇ and THR ⁇ were used as "bait" to screen the compound library using AlphaScreen technology.
  • AlphaScreen kit (Perkins-Elmer) experiments the ability of THR and LBD proteins to bind to ligands to recruit various peptides with different motifs can be detected (Jin et al., Nature communication 2013, 4, 1937).
  • the reaction system of this experiment is 20-80nM acceptor LBD protein, 20nM biotinylated cofactor polypeptide, 5 ⁇ g / ml donor and acceptor glass beads, buffer solution (25mM Hepes, 100mM NaCl and 0.1mg / ml bovine seed serum , PH 7.0).
  • Example 2 demonstrates that FG-4592THR enhances the transcriptional activation of reporter genes in living cells and is an agonist of the thyroid hormone receptor THR.
  • plasmids encoding Gal4 DNA binding domain, reporter gene, and THRLBD were co-transfected into African green monkey kidney fibroblasts Cos7 cells.
  • Cos7 cell culture was performed using DMEM medium containing 10% fetal bovine serum, and transient transfection was performed using Lipofectamine 2000 (Invitrogen) kit.
  • 200 ng of Gal4-LBD was co-transfected with 200 ng of pG5Luc (Promega).
  • Agonist compounds were added 5h after transfection. After 24 hours of treatment, cells were collected for luciferase detection experiments.
  • the fluorescence detection experiment was performed by co-transfection of the Renilla reporter gene as an endogenous reference.
  • the efficacy of the compound (5 ⁇ M) in inducing the transcription activity of THR ⁇ and THR ⁇ wild type and mutant reporter genes is shown in Table 2.
  • the experimental results are consistent with the results of AlphaScreen.
  • FG-4592 can significantly enhance the transcriptional activation of THR ⁇ wild type and THR ⁇ wild type reporter genes.
  • FG-4592 is an agonist of thyroid hormone receptor THR and can activate THR. Mediated gene expression.
  • Example 3 demonstrates that FG-4592 has a stronger selective activation of THR ⁇ .
  • thyroid hormone receptors have two subtypes, THR ⁇ and THR ⁇ , and the activation of THR ⁇ has certain side effects on the cardiovascular system.
  • the natural thyroid hormone T3 has not shown any selectivity in binding the two THR subtypes (THR ⁇ and THR ⁇ ). Therefore, the development of existing thyroid hormone agonists is mainly to increase the selective activation of THR ⁇ and reduce the activation of THR ⁇ .
  • the Gal-4 driven reporter gene experiment was performed on THR ⁇ and THR ⁇ as in Example 2 to obtain the compound activation efficiency, and the potency EC50 was calculated using the full dose curve. The compounds induced the THR ⁇ and THR ⁇ reporter genes, respectively.
  • Efficacy is a term in pharmaceutical pharmacology, which refers to the ability of a drug to produce the maximum effect, and is used to evaluate the maximum effect of different drugs.
  • Potency also called potency strength, it refers to the dose or concentration required for a drug to produce a certain effect.
  • EC50 is the half-effect concentration, that is, the dose of a drug that causes 50% of the subjects to produce a specific effect. A smaller EC50 indicates better activity and greater strength. As shown in Table 3, compared to T3, FG-4592 has stronger selective activation of THR ⁇ in potency and potency, and is therefore a THR ⁇ selective agonist.
  • Example 4 demonstrates the analysis of the crystal structure of the complex between FG-4592 and THR ⁇ .
  • the crystal structure of the complex formed by FG-4592 and THR ⁇ was analyzed according to the conventional X-ray crystal diffraction method (Fig. 4).
  • Fig. 4 To obtain THR ⁇ protein as described in Example 1, add FG4592 5 times the amount of THR ⁇ LBD protein and SRC2-3 polypeptide (ENALLRYLLDKD) which is twice the amount of THR ⁇ LBD protein. After incubating on ice for 1 h, concentrate to 10 mg / mL. Crystallization was performed using the Hampton Crystallization Screening Kit. The sample complex was mixed with the screening buffer 1: 1, and the crystals were screened by the hanging drop method.
  • the best conditions are: 0.2M sodium citrate, 20% by volume polyethylene glycol 3350, and the crystals are directly frozen in liquid nitrogen after adding a cryoprotectant.
  • the frozen crystals were collected at Shanghai National Synchrotron Radiation Center. After the data was processed and restored by HKL3000, the structure was determined using CCP4 tool software. Coot software is used for manual modification, and software such as REFMAC is used for modification. After the structural parameter evaluation is completed, the structural analysis is completed.
  • the structure shows that the binding of FG-4592 to the THR ⁇ ligand binding domain conforms to the classic "sandwich” conformation. From the three-dimensional structure diagram, FG-4592 clearly exists in the ligand binding pocket of THR ⁇ ( Figure 4). In the complex structure, the THR ⁇ AF-2 helix bound to FG-4592 and helices H3, H4, and H5 together form a "pocket” and interact with the LXXLL motif of the co-activator SRC2. This is a typical pattern of nuclear receptors interacting with agonists.
  • the side chains of hydrophobic residues in the THR ⁇ ligand binding pockets show a change that favors FG-4592 out-of-pocket offset relative to the corresponding residues in THR ⁇ (see Figure 6).
  • the differential changes in THR ⁇ compared to THR ⁇ in the main chain and individual residue side chains are conducive to FG-4592 with a larger hydrophobic phenyl group to selectively bind ⁇ subtypes, which highlights the residues within each THR subtype
  • the hydrophobic phenyl tail of FG-4592 is the key to its selective binding to THR ⁇ .
  • Example 5 demonstrates that FG-4592 has significant activation of the THR ⁇ mutant transcriptional activity and can be used to treat thyroid hormone resistance syndrome.
  • Table 2 also lists the THR ⁇ receptor protein site lesions that select polytypes to produce thyroid hormone resistance syndrome (The Human Gene Gene Mutation Database, http://www.hgmd.cf.ac.uk) . Because these mutants change the conformation of the THR ligand binding domain (LBD), the strong binding ability of the THR ⁇ receptor protein to the thyroid hormones T3 and T4 is affected, and therefore it is resistant or insensitive to the thyroid hormones T3 and T4. THR ⁇ receptor mutations were performed using the Quick-Change site-directed mutagenesis kit (Stratagene), and Gal-4 driven reporter gene experiments were performed as in Example 2. The results are shown in Table 2.
  • Thyroid hormone T3 lost or significantly reduced activation of the reporter gene transcription of all mutants in the table.
  • FG-4592 which has a significantly different structure from thyroid hormones T3 and T4, is able to bind to these THR ⁇ receptor protein site lesions and significantly activate their transcriptional activity.
  • Table 2 shows that FG-4592 can produce higher induced transcription activity on THR ⁇ receptor protein lesions in the table than T3, so FG-4592 can be used to treat thyroid hormone resistance syndrome.
  • Example 6 FG-4592 activates the structural mechanism of THR ⁇ mutants associated with thyroid hormone resistance.
  • FG-4592 has the ability to treat thyroid hormone resistance caused by mutations in polymorphic receptor proteins. What surprised us, however, was that the sites of these mutations not only existed in the pockets of the receptor protein, such as THR ⁇ H435L, but also amino acid mutations outside the pocket, such as THR ⁇ V264D, R438H, R438W.
  • THR ⁇ H435L the pockets of the receptor protein
  • amino acid mutations outside the pocket such as THR ⁇ V264D, R438H, R438W.
  • co-crystallization of FG-4592 and ⁇ R ⁇ muteins Experiment and try to interpret them from a structural perspective.
  • FG-4592 does not rely on conformation with the correct His435 residue to form hydrogen bonds through hydrophobic interactions with THR ⁇ , thus still effectively activating the activity of THR ⁇ mutants, explaining at the atomic level Mechanism of FG-4592 in the treatment of thyroid hormone resistance syndrome.
  • Example 7 Analyze the complex key binding sites and modes of action of FG-4592 and THR ⁇ , and design FHR-4592 series of THR ⁇ selective and targeted THR ⁇ mutants, with a view to applying them in the preparation or prevention of thyroid hormones. Body-mediated diseases in pharmaceutical preparations.
  • R1 or R2 group can be O, C, F, Cl, Br or I
  • R3 can be C or N
  • R4 can be O, C or H
  • R5 can be C, O or N
  • R6 can be phenyl, heterocyclic compounds (such as five-membered heterocyclic compounds and six-membered heterocyclic compounds
  • the present invention relates to a FG-4592 compound, which is given in the preparation of an thyroid hormone receptor (THR) agonist and in the preparation of a pharmaceutical preparation for preventing or treating a thyroid hormone receptor-mediated disease.
  • the present invention relates to regulating the activity of thyroid hormone receptors, particularly the selective activation of thyroid hormone receptor ⁇ (THR ⁇ ) and its lesions, and is used for preventing or treating thyroid hormone receptor-mediated diseases such as hypothyroidism, thyroid hormone
  • THR ⁇ thyroid hormone receptor ⁇
  • the application in resistance and depression methods has good industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le composé FG-4592, l'application dans la préparation d'un agoniste du récepteur de l'hormone thyroïdienne (THR) et d'une préparation pharmaceutique pour la prévention ou le traitement de maladies médiées par le THR. La présente invention concerne l'ajustement de l'activité d'un THR, en particulier l'activation sélective de THRβ et de corps de lésion de celui-ci, et l'application dans des procédés de prévention ou de traitement de maladies médiées par le THR telles que l'hypothyroïdie, la résistance à l'hormone thyroïdienne et la dépression.
PCT/CN2019/087821 2018-05-22 2019-05-21 Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne WO2019223688A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810492095.1A CN110507655B (zh) 2018-05-22 2018-05-22 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用
CN201810492095.1 2018-05-22

Publications (1)

Publication Number Publication Date
WO2019223688A1 true WO2019223688A1 (fr) 2019-11-28

Family

ID=68617157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/087821 WO2019223688A1 (fr) 2018-05-22 2019-05-21 Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne

Country Status (2)

Country Link
CN (1) CN110507655B (fr)
WO (1) WO2019223688A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054996A1 (fr) * 2022-09-09 2024-03-14 Autobahn Therapeutics, Inc. Méthodes pour le traitement de la dépression

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
CN112274512A (zh) * 2020-11-11 2021-01-29 浙江尖峰药业有限公司 罗沙司他在抑制急性酒精性脂肪肝药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (fr) * 2003-06-06 2004-12-16 Fibrogen, Inc. Composes heteroaryliques contenant de l'azote et leur utilisation dans l'augmentation de l'erythropoietine endogene
WO2006133391A2 (fr) * 2005-06-06 2006-12-14 Fibrogen, Inc. Methode amelioree de traitement de l'anemie
WO2013134632A2 (fr) * 2012-03-09 2013-09-12 Fibrogen, Inc. Traitement de taux élevé de cholestérol
CN104892509A (zh) * 2015-06-04 2015-09-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN107468692A (zh) * 2017-08-18 2017-12-15 上海市第人民医院 HIF‑1α小分子激活剂FG‑4592在帕金森病中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107854468A (zh) * 2017-11-29 2018-03-30 中国人民解放军第二军医大学 Fg‑4592在制备防护急性放射性骨髓损伤药物中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (fr) * 2003-06-06 2004-12-16 Fibrogen, Inc. Composes heteroaryliques contenant de l'azote et leur utilisation dans l'augmentation de l'erythropoietine endogene
WO2006133391A2 (fr) * 2005-06-06 2006-12-14 Fibrogen, Inc. Methode amelioree de traitement de l'anemie
WO2013134632A2 (fr) * 2012-03-09 2013-09-12 Fibrogen, Inc. Traitement de taux élevé de cholestérol
CN104892509A (zh) * 2015-06-04 2015-09-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN107468692A (zh) * 2017-08-18 2017-12-15 上海市第人民医院 HIF‑1α小分子激活剂FG‑4592在帕金森病中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054996A1 (fr) * 2022-09-09 2024-03-14 Autobahn Therapeutics, Inc. Méthodes pour le traitement de la dépression

Also Published As

Publication number Publication date
CN110507655B (zh) 2022-10-28
CN110507655A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
US11266612B2 (en) D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
WO2019223688A1 (fr) Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne
Amato et al. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain
Blad et al. Biological and pharmacological roles of HCA receptors
CA2722314C (fr) Nouvelles approches therapeutiques pour traiter la maladie d'alzheimer et les troubles qui lui sont associes par modulation de la reponse au stress cellulaire
JP2016522831A (ja) 炎症を予防および治療するためのクリオピリン阻害剤
JP2022523376A (ja) レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
JP2002529421A (ja) 血管過浸透性の阻害方法
TW201536749A (zh) 吡唑－醇化合物及其醫藥用途
WO2007041936A1 (fr) Isomeres optiques de derives de piperazine d'alcool d'alkyle et leurs sels ainsi que leurs applications
AU2014381711A1 (en) Combinations of IKKepsilon/TBK1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators
JP5300979B2 (ja) Ｌｘｒ−アルファ過剰発現に起因する疾病の予防用及び治療用の１，２−ジチオールチオン誘導体を含有する薬学組成物
ES2274814T3 (es) Uso de compuestos carboxy tales como cloruro de 2(4-acetofenil) -2cloro-n-metil-etilamonio como agentes antiinflamatorios.
US20150224089A1 (en) COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS
Lu et al. Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists for autoimmune diseases
US20220227717A1 (en) Allosteric activators of the alpha1a-adrenergic receptor
KR20210062023A (ko) Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법
KR20200100726A (ko) 섬유증 치료용 화합물 및 조성물
Han et al. The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2
WO2017053510A1 (fr) Modulateurs de lipolyse cellulaire à petite molécule
Murray Synthetic Ligands Targeting ROR and REV-ERB to Treat Inflammatory and Metabolic Disease States
Park et al. Estrogen prevents age-dependent beige adipogenesis failure through NAMPT-controlled ER stress pathway
JP2021534141A (ja) アルコール使用障害の治療剤
Amatoa et al. GQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR) Ligand, Promotes Insulin Sensitization without Weight Gain□ S
Behrend How I treat cushing's disease.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807042

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19807042

Country of ref document: EP

Kind code of ref document: A1